Tiagabine in adult patients with generalized anxiety disorder: Results from 3 randomized, double-blind, placebo-controlled, parallel-group studies

Mark H. Pollack, Jane Tiller, Fang Xie, Madhukar H. Trivedi

Research output: Contribution to journalArticle

34 Scopus citations


The objective of these studies was to evaluate the efficacy and tolerability of tiagabine, a selective γ-aminobutyric acid reuptake inhibitor, in adult patients with generalized anxiety disorder (GAD). Patients with a diagnosis of GAD were enrolled in 1 of 3 randomized, placebo-controlled, 10-week studies. In each study, tiagabine was taken twice daily in divided doses-4, 8, or 12 mg/d in a fixed-dose study and 4-16 mg/d in two flexible-dose trials. The primary efficacy measure was the change from baseline in the 14-item Hamilton Rating Scale for Anxiety (HAM-A) total score at the final visit (last observation carried forward). Additional measures included change from baseline in the anxiety subscale of the Hospital Anxiety and Depression Scale, the Sheehan Disability Scale, and Clinical Global Impressions-Improvement scale. Tolerability was assessed via spontaneous reports as well as rating scales throughout the study period. In all 3 studies, there was no significant differentiation from placebo on the primary measure (change in HAM-A) for any tiagabine dose (P > 0.05). In the 2 flexible-dose studies, the tiagabine group showed improvements over time in the HAM-A that reached significance only in those patients who completed 10 weeks of treatment (study 2, P = 0.018; study 3, P = 0.036). The most common adverse events were dizziness, headache, nausea, fatigue, and somnolence. In conclusion, the results of these studies do not support the efficacy of tiagabine in adult patients with GAD.

Original languageEnglish (US)
Pages (from-to)308-316
Number of pages9
JournalJournal of clinical psychopharmacology
Issue number3
StatePublished - Jun 1 2008


ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this